XOMA Royalty Hits Inflection Point as Portfolio Receipts Surpass $50 Million
XOMA Royalty recently announced its financial results for Q4 2025, showcasing a strong year of growth and expansion. As the company's Chief Executive Officer, Owen Hughes, highlighted during the investor call, XOMA Royalty is approaching an inflection point where expected cash flows from royalty receipts alone should cover the core operating costs of the company.
One of the key highlights of 2025 was the addition of 22 new assets to the XOMA Royalty portfolio. This includes innovative transactions and milestone acquisitions, which further enhanced the company's prospects. Total portfolio receipts exceeded $50 million, with royalty receipts reaching $34 million, a 68% increase from fiscal year 2024.
XOMA Royalty achieved positive cash flow from operations and returned $16 million of capital through opportunistic share buybacks in 2025. The company plans to maintain a disciplined approach to capital deployment, investing in new portfolio assets while continuing to reduce its equity base, which should increase future cash flow per share.
The company has seven commercially available programs, providing a diverse and growing source of recurring receipts for investors. Several commercial stage programs are in the early stages of promising launches with potential geographic expansion ahead. For instance, Day One Biopharmaceuticals' OJEMDA and Zevra Therapeutics' MIPLYFFA have submitted marketing authorizations in the E.U., with Ipsen announcing a positive CHMP opinion recommending conditional marketing authorization for OJEMDA.
While XOMA Royalty is not immune to clinical setbacks, such as Rezolute's program for congenital hyperinsulinism and Gossamer Bio's seralutinib for pulmonary arterial hypertension demonstrating failed phase III studies, the company remains hopeful that these programs will see continued exploration in 2026. The breadth of XOMA Royalty's portfolio is expected to provide resilience and reduce binary outcomes compared to traditional drug developers.
XOMA Royalty's CEO, Owen Hughes, emphasized the significance of this year's developments, stating that it has been a foundational year for the company as they continued to execute on their strategy. The recent additions to the portfolio have positioned XOMA Royalty for future growth and expansion, making 2025 a pivotal year in the company's evolution.
XOMA Royalty's strong financial results and expanding portfolio make it an attractive investment opportunity for those seeking recurring receipts from commercial stage programs. As the company continues to execute on its strategy, investors can expect further developments that will drive growth and value creation.
